FFA
RVNC

Fairfield Financial Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fairfield Financial Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-80
Closed -$1.48K – 332
2022
Q4 		$1.48K Hold
80
– – ﹤0.01% 282
2022
Q3 		$2.16K Hold
80
– – ﹤0.01% 286
2022
Q2 		$1.11K Buy
+80
New +$1.23K ﹤0.01% 283

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fairfield Financial Advisors's RVNC Position: Q1 2023 in Review

Fairfield Financial Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 80 shares — an estimated $1.48K sold.

Fairfield Financial Advisors first reported a position in RVNC in Q2 2022 and held it in 3 quarters. The position peaked at $2.16K in Q3 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • Fairfield Financial Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 80 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $1.48K.
  • Fairfield Financial Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 3 quarters.
  • Fairfield Financial Advisors's Revance Therapeutics, Inc. position peaked at $2.16K in Q3 2022.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Fairfield Financial Advisors's 13F filing for Q1 2023, filed 4 Nov 2024.